Download PDF
Journal of Pediatric Epilepsy 2018; 07(02): 069-075
DOI: 10.1055/s-0038-1668589
Review Article
Georg Thieme Verlag KG Stuttgart · New York

Immunotherapy in Autoimmune and Neuroinflammation-Related Epilepsies

Kapil Arya
1   Department of Pediatrics, Section of Child Neurology, Arkansas Children's Hospital, University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States
,
Erin Willis
1   Department of Pediatrics, Section of Child Neurology, Arkansas Children's Hospital, University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States
,
Debopam Samanta
1   Department of Pediatrics, Section of Child Neurology, Arkansas Children's Hospital, University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States
› Author Affiliations
Further Information

Publication History

02 June 2018

20 June 2018

Publication Date:
03 September 2018 (online)

Also available at
    Permissions and Reprints

Abstract

There is increasing recognition of the role played by neuroinflammation both as a factor in the development of epilepsy as well as a consequence of seizures. Autoimmune encephalitis and epilepsies have emerged as an important etiology of drug-refractory epilepsies. The recognition of these entities is vital for immunomodulation and is the cornerstone in its management. Immunotherapy treatment regimens in these conditions continue to be refined, and there is an increasing knowledge in their use. This article attempts to review the experience with the use of different immunotherapies in specific autoimmune and neuroinflammation-related encephalitis and epilepsies including their mechanisms of action and potential side effects.

Keywords

neuroinflammation - epilepsy - therapy
 

  • References

  • 1 Pernot F, Heinrich C, Barbier L. , et al. Inflammatory changes during epileptogenesis and spontaneous seizures in a mouse model of mesiotemporal lobe epilepsy. Epilepsia 2011; 52 (12) 2315-2325
    CrossrefPubMedGoogle Scholar
  • 2 Bauer J, Becker AJ, Elyaman W. , et al. Innate and adaptive immunity in human epilepsies. Epilepsia 2017; 58 (Suppl. 03) 57-68
    CrossrefPubMedGoogle Scholar
  • 3 Correll CM. Antibodies in epilepsy. Curr Neurol Neurosci Rep 2013; 13 (05) 348
    CrossrefPubMedGoogle Scholar
  • 4 Bien CG. Value of autoantibodies for prediction of treatment response in patients with autoimmune epilepsy: review of the literature and suggestions for clinical management. Epilepsia 2013; 54 (Suppl. 02) 48-55
    CrossrefPubMedGoogle Scholar
  • 5 Shin YW, Lee ST, Park KI. , et al. Treatment strategies for autoimmune encephalitis. Ther Adv Neurol Disorder 2017; 11: 1756285617722347
    PubMedGoogle Scholar
  • 6 Graus F, Titulaer MJ, Balu R. , et al. A clinical approach to diagnosis of autoimmune encephalitis. Lancet Neurol 2016; 15 (04) 391-404
    CrossrefPubMedGoogle Scholar
  • 7 Byrne S, Walsh C, Hacohen Y. , et al. Earlier treatment of NMDAR antibody encephalitis in children results in a better outcome. Neurol Neuroimmunol Neuroinflamm 2015; 2 (04) e130
    CrossrefPubMedGoogle Scholar
  • 8 Quek AM, Britton JW, McKeon A. , et al. Autoimmune epilepsy: clinical characteristics and response to immunotherapy. Arch Neurol 2012; 69 (05) 582-593
    CrossrefPubMedGoogle Scholar
  • 9 Melvin JJ, Huntley Hardison H. Immunomodulatory treatments in epilepsy. Semin Pediatr Neurol 2014; 21 (03) 232-237
    CrossrefPubMedGoogle Scholar
  • 10 Witt KA, Sandoval KE. Steroids and the blood-brain barrier: therapeutic implications. Adv Pharmacol 2014; 71: 361-390
    PubMedGoogle Scholar
  • 11 Tuem KB, Atey TM. Neuroactive steroids: receptor interactions and responses. Front Neurol 2017; 8: 442
    CrossrefPubMedGoogle Scholar
  • 12 Wong PH, White KM. Impact of immunoglobulin therapy in pediatric disease: a review of immune mechanisms. Clin Rev Allergy Immunol 2016; 51 (03) 303-314
    CrossrefPubMedGoogle Scholar
  • 13 Kaneko Y, Nimmerjahn F, Ravetch JV. Anti-inflammatory activity of immunoglobulin G resulting from Fc sialylation. Science 2006; 313 (5787): 670-673
    CrossrefPubMedGoogle Scholar
  • 14 Tackenberg B, Jelcic I, Baerenwaldt A. , et al. Impaired inhibitory Fcgamma receptor IIB expression on B cells in chronic inflammatory demyelinating polyneuropathy. Proc Natl Acad Sci U S A 2009; 106 (12) 4788-4792
    CrossrefPubMedGoogle Scholar
  • 15 Samuelsson A, Towers TL, Ravetch JV. Anti-inflammatory activity of IVIG mediated through the inhibitory Fc receptor. Science 2001; 291 (5503): 484-486
    CrossrefPubMedGoogle Scholar
  • 16 Jacob S, Rajabally YA. Current proposed mechanisms of action of intravenous immunoglobulins in inflammatory neuropathies. Curr Neuropharmacol 2009; 7 (04) 337-342
    CrossrefPubMedGoogle Scholar
  • 17 Durandy A, Kaveri SV, Kuijpers TW. , et al. Intravenous immunoglobulins–understanding properties and mechanisms. Clin Exp Immunol 2009; 158 (Suppl. 01) 2-13
    CrossrefPubMedGoogle Scholar
  • 18 Lehmann HC, Hartung HP, Hetzel GR, Stüve O, Kieseier BC. Plasma exchange in neuroimmunological disorders: part 1: rationale and treatment of inflammatory central nervous system disorders. Arch Neurol 2006; 63 (07) 930-935
    CrossrefPubMedGoogle Scholar
  • 19 DeSena AD, Noland DK, Matevosyan K. , et al. Intravenous methylprednisolone versus therapeutic plasma exchange for treatment of anti-N-methyl-D-aspartate receptor antibody encephalitis: a retrospective review. J Clin Apher 2015; 30 (04) 212-216
    CrossrefPubMedGoogle Scholar
  • 20 Dogan Onugoren M, Golombeck KS, Bien C. , et al. Immunoadsorption therapy in autoimmune encephalitides. Neurol Neuroimmunol Neuroinflamm 2016; 3 (02) e207
    CrossrefPubMedGoogle Scholar
  • 21 Lancaster E, Martinez-Hernandez E, Dalmau J. Encephalitis and antibodies to synaptic and neuronal cell surface proteins. Neurology 2011; 77 (02) 179-189
    CrossrefPubMedGoogle Scholar
  • 22 Gottenberg JE, Guillevin L, Lambotte O. , et al; Club Rheumatismes et Inflammation (CRI). Tolerance and short term efficacy of rituximab in 43 patients with systemic autoimmune diseases. Ann Rheum Dis 2005; 64 (06) 913-920
    CrossrefPubMedGoogle Scholar
  • 23 Hauser SL, Waubant E, Arnold DL. , et al; HERMES Trial Group. B-cell depletion with rituximab in relapsing-remitting multiple sclerosis. N Engl J Med 2008; 358 (07) 676-688
    CrossrefPubMedGoogle Scholar
  • 24 Memon AB, Javed A, Caon C. , et al. Long-term safety of rituximab induced peripheral B-cell depletion in autoimmune neurological diseases. PLoS One 2018; 13 (01) e0190425
    CrossrefPubMedGoogle Scholar
  • 25 Lee WJ, Lee ST, Byun JI. , et al. Rituximab treatment for autoimmune limbic encephalitis in an institutional cohort. Neurology 2016; 86 (18) 1683-1691
    CrossrefPubMedGoogle Scholar
  • 26 Wang BJ, Wang CJ, Zeng ZL, Yang Y, Guo SG. Lower dosages of rituximab used successfully in the treatment of anti-NMDA receptor encephalitis without tumour. J Neurol Sci 2017; 377: 127-132
    CrossrefPubMedGoogle Scholar
  • 27 Winkelstein A. Mechanisms of immunosuppression: effects of cyclophosphamide on cellular immunity. Blood 1973; 41 (02) 273-284
    CrossrefPubMedGoogle Scholar
  • 28 McKeon A. Immunotherapeutics for autoimmune encephalopathies and dementias. Curr Treat Options Neurol 2013; 15 (06) 723-737
    CrossrefPubMedGoogle Scholar
  • 29 Carreño M, Bien CG, Asadi-Pooya AA. , et al. Epilepsy surgery in drug resistant temporal lobe epilepsy associated with neuronal antibodies. Epilepsy Res 2017; 129: 101-105
    CrossrefPubMedGoogle Scholar
  • 30 Scheibe F, Prüss H, Mengel AM. , et al. Bortezomib for treatment of therapy-refractory anti-NMDA receptor encephalitis. Neurology 2017; 88 (04) 366-370
    CrossrefPubMedGoogle Scholar
  • 31 Lee WJ, Lee ST, Moon J. , et al. Tocilizumab in autoimmune encephalitis refractory to rituximab: an institutional cohort study. Neurotherapeutics 2016; 13 (04) 824-832
    CrossrefPubMedGoogle Scholar
  • 32 Brenton JN, Kim J, Schwartz RH. Approach to the management of pediatric-onset anti-N-methyl-D-aspartate (anti-NMDA) receptor encephalitis: a case series. J Child Neurol 2016; 31 (09) 1150-1155
    CrossrefPubMedGoogle Scholar
  • 33 Zhang L, Wu MQ, Hao ZL. , et al. Clinical characteristics, treatments, and outcomes of patients with anti-N-methyl-D-aspartate receptor encephalitis: a systematic review of reported cases. Epilepsy Behav 2017; 68: 57-65
    CrossrefPubMedGoogle Scholar
  • 34 Titulaer MJ, McCracken L, Gabilondo I. , et al. Treatment and prognostic factors for long-term outcome in patients with anti-NMDA receptor encephalitis: an observational cohort study. Lancet Neurol 2013; 12 (02) 157-165
    CrossrefPubMedGoogle Scholar
  • 35 Bartolini L, Muscal E. Differences in treatment of anti-NMDA receptor encephalitis: results of a worldwide survey. J Neurol 2017; 264 (04) 647-653
    CrossrefPubMedGoogle Scholar
  • 36 Herranz-Pérez V, Olucha-Bordonau FE, Morante-Redolat JM, Pérez-Tur J. Regional distribution of the leucine-rich glioma inactivated (LGI) gene family transcripts in the adult mouse brain. Brain Res 2010; 1307: 177-194
    CrossrefPubMedGoogle Scholar
  • 37 Lovero KL, Fukata Y, Granger AJ, Fukata M, Nicoll RA. The LGI1-ADAM22 protein complex directs synapse maturation through regulation of PSD-95 function. Proc Natl Acad Sci U S A 2015; 112 (30) E4129-E4137
    CrossrefPubMedGoogle Scholar
  • 38 Fukata Y, Lovero KL, Iwanaga T. , et al. Disruption of LGI1-linked synaptic complex causes abnormal synaptic transmission and epilepsy. Proc Natl Acad Sci U S A 2010; 107 (08) 3799-3804
    CrossrefPubMedGoogle Scholar
  • 39 Kalachikov S, Evgrafov O, Ross B. , et al. Mutations in LGI1 cause autosomal-dominant partial epilepsy with auditory features. Nat Genet 2002; 30 (03) 335-341
    CrossrefPubMedGoogle Scholar
  • 40 Lai M, Huijbers MG, Lancaster E. , et al. Investigation of LGI1 as the antigen in limbic encephalitis previously attributed to potassium channels: a case series. Lancet Neurol 2010; 9 (08) 776-785
    CrossrefPubMedGoogle Scholar
  • 41 Andrade DM, Tai P, Dalmau J, Wennberg R. Tonic seizures: a diagnostic clue of anti-LGI1 encephalitis?. Neurology 2011; 76 (15) 1355-1357
    CrossrefPubMedGoogle Scholar
  • 42 Irani SR, Michell AW, Lang B. , et al. Faciobrachial dystonic seizures precede Lgi1 antibody limbic encephalitis. Ann Neurol 2011; 69 (05) 892-900
    CrossrefPubMedGoogle Scholar
  • 43 Kotsenas AL, Watson RE, Pittock SJ. , et al. MRI findings in autoimmune voltage-gated potassium channel complex encephalitis with seizures: one potential etiology for mesial temporal sclerosis. Am J Neuroradiol 2014; 35 (01) 84-89
    CrossrefPubMedGoogle Scholar
  • 44 Ariño H, Armangué T, Petit-Pedrol M. , et al. Anti-LGI1-associated cognitive impairment: presentation and long-term outcome. Neurology 2016; 87 (08) 759-765
    CrossrefPubMedGoogle Scholar
  • 45 Bhardwaj K, Sharma SK, Pandey AK, Upadhyay V. A case of limbic encephalitis: antibody LGI1 associated encephalitis. J Neurol Neurosci. 2016; 7: 4 . doi: 10.21767/2171-6625.1000137
    PubMedGoogle Scholar
  • 46 Szots M, Marton A, Kover F. , et al. Natural course of LGI1 encephalitis: 3-5 years of follow-up without immunotherapy. J Neurol Sci 2014; 343 (1–2): 198-202
    CrossrefPubMedGoogle Scholar
  • 47 Finke C, Prüss H, Heine J. , et al. Evaluation of cognitive deficits and structural hippocampal damage in encephalitis with leucine-rich, glioma-inactivated 1 antibodies. JAMA Neurol 2017; 74 (01) 50-59
    CrossrefPubMedGoogle Scholar
  • 48 Manto MU, Laute MA, Aguera M, Rogemond V, Pandolfo M, Honnorat J. Effects of anti-glutamic acid decarboxylase antibodies associated with neurological diseases. Ann Neurol 2007; 61 (06) 544-551
    CrossrefPubMedGoogle Scholar
  • 49 Sloviter RS, Dichter MA, Rachinsky TL. , et al. Basal expression and induction of glutamate decarboxylase and GABA in excitatory granule cells of the rat and monkey hippocampal dentate gyrus. J Comp Neurol 1996; 373 (04) 593-618
    CrossrefPubMedGoogle Scholar
  • 50 Daif A, Lukas RV, Issa NP. , et al. Antiglutamic acid decarboxylase 65 (GAD65) antibody-associated epilepsy. Epilepsy Behav 2018; 80: 331-336
    CrossrefPubMedGoogle Scholar
  • 51 Malter MP, Frisch C, Zeitler H. , et al. Treatment of immune-mediated temporal lobe epilepsy with GAD antibodies. Seizure 2015; 30: 57-63
    CrossrefPubMedGoogle Scholar
  • 52 Saidha S, Murphy S, Ronayne A, McCarthy P, Hennessy MJ, Counihan T. Treatment of anti-glutamic acid decarboxylase antibody-associated limbic encephalitis with mycophenolate mofetil. J Neurol 2010; 257 (06) 1035-1038
    CrossrefPubMedGoogle Scholar
  • 53 Lilleker JB, Biswas V, Mohanraj R. Glutamic acid decarboxylase (GAD) antibodies in epilepsy: diagnostic yield and therapeutic implications. Seizure 2014; 23 (08) 598-602
    CrossrefPubMedGoogle Scholar
  • 54 Holzer FJ, Rossetti AO, Heritier-Barras AC. , et al. Antibody-mediated status epilepticus: a retrospective multicenter survey. Eur Neurol 2012; 68 (05) 310-317
    CrossrefPubMedGoogle Scholar
  • 55 Khawaja AM, Vines BL, Miller DW, Szaflarski JP, Amara AW. Refractory status epilepticus and glutamic acid decarboxylase antibodies in adults: presentation, treatment and outcomes. Epileptic Disord 2016; 18 (01) 34-43
    PubMedGoogle Scholar
  • 56 Heiry M, Afra P, Matsuo F, Greenlee JE, Clardy SL. Improvement of GAD65-associated autoimmune epilepsy with testosterone replacement therapy. Neurol Neuroimmunol Neuroinflamm 2015; 2 (05) e142
    CrossrefPubMedGoogle Scholar
  • 57 Bien CG, Granata T, Antozzi C. , et al. Pathogenesis, diagnosis and treatment of Rasmussen encephalitis: a European consensus statement. Brain 2005; 128 (Pt 3): 454-471
    CrossrefPubMedGoogle Scholar
  • 58 Pardo CA, Vining EPG, Guo L, Skolasky RL, Carson BS, Freeman JM. The pathology of Rasmussen syndrome: stages of cortical involvement and neuropathological studies in 45 hemispherectomies. Epilepsia 2004; 45 (05) 516-526
    CrossrefPubMedGoogle Scholar
  • 59 Farrell MA, DeRosa MJ, Curran JG. , et al. Neuropathologic findings in cortical resections (including hemispherectomies) performed for the treatment of intractable childhood epilepsy. Acta Neuropathol 1992; 83 (03) 246-259
    CrossrefPubMedGoogle Scholar
  • 60 Farrell MA, Droogan O, Secor DL, Poukens V, Quinn B, Vinters HV. Chronic encephalitis associated with epilepsy: immunohistochemical and ultrastructural studies. Acta Neuropathol 1995; 89 (04) 313-321
    CrossrefPubMedGoogle Scholar
  • 61 Ransohoff RM, Perry VH. Microglial physiology: unique stimuli, specialized responses. Annu Rev Immunol 2009; 27: 119-145
    CrossrefPubMedGoogle Scholar
  • 62 Bien CG, Bauer J, Deckwerth TL. , et al. Destruction of neurons by cytotoxic T cells: a new pathogenic mechanism in Rasmussen's encephalitis. Ann Neurol 2002; 51 (03) 311-318
    CrossrefPubMedGoogle Scholar
  • 63 Rogers SW, Andrews PI, Gahring LC. , et al. Autoantibodies to glutamate receptor GluR3 in Rasmussen's encephalitis. Science 1994; 265 (5172): 648-651
    CrossrefPubMedGoogle Scholar
  • 64 Alvarez-Barón E, Bien CG, Schramm J, Elger CE, Becker AJ, Schoch S. Autoantibodies to Munc18, cerebral plasma cells and B-lymphocytes in Rasmussen encephalitis. Epilepsy Res 2008; 80 (01) 93-97
    CrossrefPubMedGoogle Scholar
  • 65 Yang R, Puranam RS, Butler LS. , et al. Autoimmunity to munc-18 in Rasmussen's encephalitis. Neuron 2000; 28 (02) 375-383
    CrossrefPubMedGoogle Scholar
  • 66 Walter GF, Renella RR. Epstein-Barr virus in brain and Rasmussen's encephalitis. Lancet 1989; 1 (8632): 279-280
    PubMedGoogle Scholar
  • 67 Power C, Poland SD, Blume WT, Girvin JP, Rice GP. Cytomegalovirus and Rasmussen's encephalitis. Lancet 1990; 336 (8726): 1282-1284
    CrossrefPubMedGoogle Scholar
  • 68 Vinters HV, Wang R, Wiley CA. Herpesviruses in chronic encephalitis associated with intractable childhood epilepsy. Hum Pathol 1993; 24 (08) 871-879
    CrossrefPubMedGoogle Scholar
  • 69 Vining EP, Freeman JM, Pillas DJ. , et al. Why would you remove half a brain? The outcome of 58 children after hemispherectomy-the Johns Hopkins experience: 1968 to 1996. Pediatrics 1997; 100 (2 Pt 1): 163-171
    CrossrefPubMedGoogle Scholar
  • 70 Devlin AM, Cross JH, Harkness W. , et al. Clinical outcomes of hemispherectomy for epilepsy in childhood and adolescence. Brain 2003; 126 (Pt 3): 556-566
    CrossrefPubMedGoogle Scholar
  • 71 Griessenauer CJ, Salam S, Hendrix P. , et al. Hemispherectomy for treatment of refractory epilepsy in the pediatric age group: a systematic review. J Neurosurg Pediatr 2015; 15 (01) 34-44
    CrossrefPubMedGoogle Scholar
  • 72 Andrews PI, Dichter MA, Berkovic SF, Newton MR, McNamara JO. Plasmapheresis in Rasmussen's encephalitis. 1996. Neurology 2001; 57 (11) (Suppl. 04) S37-S41
    CrossrefPubMedGoogle Scholar
  • 73 Antozzi C, Granata T, Aurisano N. , et al. Long-term selective IgG immuno-adsorption improves Rasmussen's encephalitis. Neurology 1998; 51 (01) 302-305
    CrossrefPubMedGoogle Scholar
  • 74 Thilo B, Stingele R, Knudsen K. , et al. A case of Rasmussen encephalitis treated with rituximab. Nat Rev Neurol 2009; 5 (08) 458-462
    PubMedGoogle Scholar
  • 75 Maria BL, Ringdahl DM, Mickle JP. , et al. Intraventricular alpha interferon therapy for Rasmussen's syndrome. Can J Neurol Sci 1993; 20 (04) 333-336
    PubMedGoogle Scholar
  • 76 Granata T, Fusco L, Gobbi G. , et al. Experience with immunomodulatory treatments in Rasmussen's encephalitis. Neurology 2003; 61 (12) 1807-1810
    CrossrefPubMedGoogle Scholar
  • 77 van Baalen A, Häusler M, Boor R. , et al. Febrile infection-related epilepsy syndrome (FIRES): a nonencephalitic encephalopathy in childhood. Epilepsia 2010; 51 (07) 1323-1328
    CrossrefPubMedGoogle Scholar
  • 78 van Baalen A, Häusler M, Plecko-Startinig B. , et al. Febrile infection-related epilepsy syndrome without detectable autoantibodies and response to immunotherapy: a case series and discussion of epileptogenesis in FIRES. Neuropediatrics 2012; 43 (04) 209-216
    Article in Thieme ConnectPubMedGoogle Scholar
  • 79 Kramer U, Chi CS, Lin KL. , et al. Febrile infection-related epilepsy syndrome (FIRES): pathogenesis, treatment, and outcome: a multicenter study on 77 children. Epilepsia 2011; 52 (11) 1956-1965
    CrossrefPubMedGoogle Scholar
  • 80 Kenney-Jung DL, Vezzani A, Kahoud RJ. , et al. Febrile infection-related epilepsy syndrome treated with anakinra. Ann Neurol 2016; 80 (06) 939-945
    CrossrefPubMedGoogle Scholar
  • 81 Ismail FY, Kossoff EH. AERRPS, DESC, NORSE, FIRES: multi-labeling or distinct epileptic entities?. Epilepsia 2011; 52 (11) e185-e189
    CrossrefPubMedGoogle Scholar
  • 82 Gall CR, Jumma O, Mohanraj R. Five cases of new onset refractory status epilepticus (NORSE) syndrome: outcomes with early immunotherapy. Seizure 2013; 22 (03) 217-220
    CrossrefPubMedGoogle Scholar
  • 83 Li J, Saldivar C, Maganti RK. Plasma exchange in cryptogenic new onset refractory status epilepticus. Seizure 2013; 22 (01) 70-73
    CrossrefPubMedGoogle Scholar